Abstract
Biotechnology Law ReportVol. 36, No. 5 Holman ReportFDA's Efforts to Tame the “Wild West” of Regenerative MedicineChristopher M. HolmanChristopher M. HolmanSearch for more papers by this authorPublished Online:1 Oct 2017https://doi.org/10.1089/blr.2017.29033.cmhAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byArguments for a Different Regulatory Categorization and Framework for Stromal Vascular Fraction Ricardo L. Rodriguez, Trivia Frazier, Bruce A. Bunnell, Cecilia A. Mouton, Keith L. March, Adam J. Katz, J. Peter Rubin, Ramon Llull, Jens A. Sørensen, and Jeffrey M. Gimble27 February 2020 | Stem Cells and Development, Vol. 29, No. 5 Volume 36Issue 5Oct 2017 InformationCopyright 2017, Mary Ann Liebert, Inc.To cite this article:Christopher M. Holman.FDA's Efforts to Tame the “Wild West” of Regenerative Medicine.Biotechnology Law Report.Oct 2017.217-222.http://doi.org/10.1089/blr.2017.29033.cmhPublished in Volume: 36 Issue 5: October 1, 2017PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
